Please use this identifier to cite or link to this item: https://doi.org/10.1080/01676830.2018.1553189
Title: Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease
Authors: Young, SM 
Lim, AYN 
Lang, SS
Lee, KO 
Sundar, G 
Keywords: Pulsed IVMP
active TED
efficacy and safety
medical management
steroid sparing agents
Adolescent
Adult
Aged
Female
Glucocorticoids
Graves Ophthalmopathy
Humans
Infusions, Intravenous
Male
Methylprednisolone
Middle Aged
Prospective Studies
Pulse Therapy, Drug
Treatment Outcome
Young Adult
Issue Date: 3-Sep-2019
Publisher: Informa UK Limited
Citation: Young, SM, Lim, AYN, Lang, SS, Lee, KO, Sundar, G (2019-09-03). Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease. Orbit (London) 38 (5) : 362-369. ScholarBank@NUS Repository. https://doi.org/10.1080/01676830.2018.1553189
Abstract: Introduction: The mainstay of therapy for active inflammatory phase of thyroid eye disease (TED) is immunosuppression. Patients in our centre with early active TED are treated with pulsed intravenous methylprednisolone (IVMP). Two different protocols are offered in our centre: High dose (1g/day for 3 days, monthly for 6 months), or EUGOGO protocol (500 mg weekly for six weeks, followed by 250 mg weekly for the next 6 weeks). Methods: A prospective cohort study of patients undergoing the two IVMP protocols was performed from January 2009 to May 2015. Main outcome measures were improvement of Clinical Activity Score (CAS) and International Thyroid Eye Disease (ITEDS)–VISA Inflammatory Index. Results: We had a total of 63 patients. Mean age was 43.1 ± 13.1years, females comprised 49.2% (n = 31), and 31 (49.2%) had a positive smoking history. Following IVMP, 65.0% (n = 41) had good response, 31.7% (n = 20) partial, and 3.3% (n = 2) poor. There were significant differences (p < 0.001) in CAS and ITEDS scores between pre-IVMP and post-IVMP visits, for both protocols. A higher proportion of patients receiving the modified EUGOGO protocol (58.3%) had persistent activity and required additional immunosuppression compared to those who underwent the high dose protocol (33.3%). Mild side effects were experienced by 5 (7.9%) and 3 (4.8%) patients at 3 and 6 months, respectively. There were no severe side effects, cardiovascular events or liver failure. Conclusion: With adequate screening and follow-up, six repeated cycles of high dose pulsed IVMP is an effective treatment for TED and can significantly reduce the morbidity associated with this debilitating condition. None of the 51 patients from the high dose protocol met with any serious side effects.
Source Title: Orbit (London)
URI: https://scholarbank.nus.edu.sg/handle/10635/205961
ISSN: 01676830
17445108
DOI: 10.1080/01676830.2018.1553189
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
EfficSafetyPulsedIVMethylPredEarlyActiveThyroidEyeDisease.pdfPublished version1.18 MBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

7
checked on May 14, 2022

Page view(s)

47
checked on May 12, 2022

Download(s)

1
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.